Improvement of peripheral blood flow following autologous peripheral mononuclear cells transplantation in patients with peripheral arterial diseases

Improvement of peripheral blood flow following autologous peripheral mononuclear cells transplantation in patients with peripheral arterial diseases - Autologous peripheral mononuclear cells transplantation for peripheral arterial diseases

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001597

Enrollment

Registered

2008-12-24

Start date

2005-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peripheral arterial diseases

Interventions

intramuscular administration of peripheral mononuclear cells collected by blood separator

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with arteriosclerosis obliterans diagnosed as Fontaine's classification III or IV, or patients with Buerger's disease Patients who were disclosed their arterial disease and agreed with enrollment into the study by document

Exclusion criteria

Exclusion criteria: Patients intolerable for extracorporeal circulation Congestive heart failure (ejection fraction <50%) Renal failure (serum creatinine < 1.6 mg/dL) Women on (possible) pregnancy or lactation Patients judged inadequate by doctor in charge of the patient or the study

Design outcomes

Primary

Measure	Time frame
Subjective ischemic symptoms	—

Secondary

Measure	Time frame
Improvement of arterial blood flow Neovascularization Time to amputation	—

Countries

Japan

Contacts

Public ContactMitsuaki Tanaka

National Hospital Organization Awara Hospital Department of Pharmacy

nhoawara-secretary@umin.ac.jp0776-79-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026